Your browser doesn't support javascript.
loading
Rosiglitazone attenuates cerebral vasospasm and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage.
Lin, Bo-Feng; Kuo, Chan-Yang; Wen, Li-Li; Chen, Chun-Mei; Chang, Ya-Feng; Wong, Chih-Shung; Cherng, Chen-Hwan; Chuang, Mei-Yu; Wu, Zhi-Fu.
Afiliação
  • Lin BF; Department of Anesthesiology, Tri-Service General Hospital, National Defense Medical Center, #325, Section 2 Chenggung Road, Neihu 114, Taipei, Taiwan, ROC, bflin0114@gmail.com.
Neurocrit Care ; 21(2): 316-31, 2014 Oct.
Article em En | MEDLINE | ID: mdl-25022803
ABSTRACT

BACKGROUND:

Glutamate and oxidative stress play important roles after subarachnoid hemorrhage (SAH). The ability to modulate glutamate transporter 1 (GLT-1) and the antioxidative effect of rosiglitazone have been demonstrated. We investigated the neuroprotective effect of rosiglitazone after SAH.

METHODS:

SAH was induced by double blood injection. The rats were randomly divided into sham, SAH + vehicle, and SAH + rosiglitazone groups and treated with dimethyl sulfoxide, dimethyl sulfoxide, and 6 mg/kg of rosiglitazone, respectively, at 2 and 12 h after SAH induction and then daily for 6 days. Cerebrospinal fluid dialysates were collected 30 min before SAH induction and then daily for 7 days for glutamate measurement. Mortality, body weight, and neurological scores were also measured daily. On day 7 after SAH, the wall thickness and the perimeter of the basilar artery (BA), neuron variability, GLT-1 levels, glial fibrillary acidic protein (GFAP) expression and activity, and malondialdehyde, superoxide dismutase, and catalase activities were also evaluated.

RESULTS:

Rosiglitazone improved survival (relative risk = 0.325) and neurological functions and reduced neuronal degeneration (5.7 ± 0.8 vs. 10.0 ± 0.9; P < 0.001) compared with the SAH + vehicle group. Rosiglitazone also lowered glutamate levels by 43.5-fold and upregulated GLT-1 expression by 1.5-fold and astrocyte activity by 1.8-fold compared with the SAH + vehicle group. The increase in BA wall thickness was significantly attenuated by rosiglitazone, whereas the perimeter of the BA was increased. In addition, rosiglitazone abated the 1.9-fold increase in malondialdehyde levels and the 1.6-fold increase in catalase activity after SAH.

CONCLUSION:

Rosiglitazone reduced SAH mortality, neurological deficits, body weight loss, GFAP loss, and cerebral vasospasm by preventing the neurotoxicity induced by glutamate and oxidative stress.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Subaracnóidea / Fármacos Neuroprotetores / Vasoespasmo Intracraniano / Tiazolidinedionas Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Neurocrit Care Assunto da revista: NEUROLOGIA / TERAPIA INTENSIVA Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Subaracnóidea / Fármacos Neuroprotetores / Vasoespasmo Intracraniano / Tiazolidinedionas Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Neurocrit Care Assunto da revista: NEUROLOGIA / TERAPIA INTENSIVA Ano de publicação: 2014 Tipo de documento: Article